当前蛋白身份:O15151 重新检索
本组结构的主要差异维度
构建体不同 突变/修饰不同 组装状态不同 配体/离子不同 实验方法不同 实验环境不同 结构质量指标不同

差异标签只比较当前检索结果;所有PDB和assembly原始记录仍分别保留。

相关结构差异明细

一行代表一个 PDB 条目中的一个 biological assembly;同一蛋白的多个单体会分别列出。

PDB 条目 Assembly / 聚集状态 构建体 突变与修饰 配体、离子与非聚合物 实验方法 实验环境 结构质量
2CR8 Solution structure of the zf-RanBP domain of p53-binding protein Mdm4 提交 2005-05-20 Assembly 1 蛋白单体 单体;蛋白 × 1 PDB 声明:monomeric(1) 与蛋白数一致
链 A 300–339(40 aa) 片段:zf-RanBP domain
未记录 ZN ZINC ION × 1 SOLUTION NMR
NMR测量条件 pH 7;298 K;离子强度(mmCIF原始值)120mM;压力 ambient
NMR样品组成 0.42mM 13C, 15N-labeled protein; 20mM d-Tris-HCl (pH7.0); 200mM NaCl; 1mM d-DTT; 0.02% NaN3; 0.01mM ZnCl2 | 90% H2O/10% D2O
分辨率未提供
2MWY Mdmx-p53 提交 2014-12-03 Assembly 1 蛋白异源复合物 异源复合物;蛋白 × 2 PDB 声明:dimeric(2) 与蛋白数一致
链 A 23–111(89 aa) 片段:SWIB domain residues 23-111
未记录 未记录非水小分子 SOLUTION NMR
NMR测量条件 pH 7;298 K;离子强度(mmCIF原始值)200;压力 ambient
NMR样品组成 1.0 mM [U-100% 13C; U-100% 15N] protein 1, 1.2 mM protein 2, 90% H2O/10% D2O | 90% H2O/10% D2O
分辨率未提供
2N06 Mdmx-298 提交 2015-03-04 Assembly 1 蛋白单体 单体;蛋白 × 1 PDB 声明:monomeric(1) 与蛋白数一致
链 A 23–111(89 aa) 片段:UNP residues 23-111
未记录 44Z 4-[[(4S,5R)-5-(4-chlorophenyl)-4-(3-methoxyphenyl)-2-(4-methoxy-2-propan-2-yloxy-phenyl)-4,5-dihydroimidazol-1-yl]carbonyl]piperazin-2-one × 1 SOLUTION NMR
NMR测量条件 pH 6.5;298 K;离子强度(mmCIF原始值)200;压力 ambient
NMR样品组成 1.0 mM [U-100% 13C; U-100% 15N] entity_1-1, 1.0 mM SJ298-2, 0.2 mM sodium chloride-3, 0.01 mM DTT-4, 90% H2O/10% D2O | 90% H2O/10% D2O
分辨率未提供
2N0U Mdmx-057 提交 2015-03-17 Assembly 1 蛋白单体 单体;蛋白 × 1 PDB 声明:monomeric(1) 与蛋白数一致
链 A 23–111(89 aa) 片段:UNP residues 23-111
未记录 48M 4-[(4S,5R)-4-(3-chlorophenyl)-5-(4-chlorophenyl)-1-(3-oxidanylidenepiperazin-1-yl)carbonyl-4,5-dihydroimidazol-2-yl]-3-propan-2-yloxy-benzenecarbonitrile × 1 SOLUTION NMR
NMR测量条件 pH 6.5;298 K;离子强度(mmCIF原始值)200;压力 ambient
NMR样品组成 0.5 mM [U-100% 13C; U-100% 15N] protein_1, 0.6 mM protein_2, 90% H2O/10% D2O | 90% H2O/10% D2O
分辨率未提供
2N0W Mdmx-SJ212 提交 2015-03-17 Assembly 1 蛋白单体 单体;蛋白 × 1 PDB 声明:monomeric(1) 与蛋白数一致
链 A 23–111(89 aa) 片段:UNP residues 23-111
未记录 48L 4-({(4S,5R)-4-(5-bromo-2-fluorophenyl)-5-(4-chlorophenyl)-2-[4-methoxy-2-(propan-2-yloxy)phenyl]-4,5-dihydro-1H-imidazol-1-yl}carbonyl)piperazin-2-one × 1 SOLUTION NMR
NMR测量条件 pH 6.5;298 K;离子强度(mmCIF原始值)200;压力 ambient
NMR样品组成 0.5 mM [U-100% 13C; U-100% 15N] protein_1, 0.6 mM protein_2, 90% H2O/10% D2O | 90% H2O/10% D2O
分辨率未提供
2N14 Mdmx-295 提交 2015-03-20 Assembly 1 蛋白单体 单体;蛋白 × 1 PDB 声明:monomeric(1) 与蛋白数一致
链 A 23–111(89 aa) 片段:UNP residues 23-111
未记录 49H 4-({(4S,5R)-4-(3-chlorophenyl)-5-(4-chlorophenyl)-2-[4-methoxy-2-(propan-2-yloxy)phenyl]-4,5-dihydro-1H-imidazol-1-yl}carbonyl)piperazin-2-one × 1 SOLUTION NMR
NMR测量条件 pH 6.5;298 K;离子强度(mmCIF原始值)200;压力 ambient
NMR样品组成 0.5 mM [U-100% 13C; U-100% 15N] protein_1, 0.6 mM protein_2, 90% H2O/10% D2O | 90% H2O/10% D2O
分辨率未提供
2VJE Crystal Structure of the MDM2-MDMX RING Domain Heterodimer 提交 2007-12-10 Assembly 1 蛋白异源复合物 异源复合物;蛋白 × 2 PDB 声明:dimeric(2) 与蛋白数一致
链 B 428–490(63 aa) 片段:RESIDUES 428-490
未记录 ZN ZINC ION × 4 X-RAY DIFFRACTION
X-ray结晶条件 pH 6.5;1.8 M NH4(SO4)2, 0.5 M NACL, 0.1 M NA CITRATE, PH 6.5
分辨率 2.20 Å R-free 0.223
2VJE Crystal Structure of the MDM2-MDMX RING Domain Heterodimer 提交 2007-12-10 Assembly 2 蛋白异源复合物 异源复合物;蛋白 × 2 PDB 声明:dimeric(2) 与蛋白数一致
链 D 428–490(63 aa) 片段:RESIDUES 428-490
未记录 ZN ZINC ION × 4 FLC CITRATE ANION × 1 SO4 SULFATE ION × 1 X-RAY DIFFRACTION
X-ray结晶条件 pH 6.5;1.8 M NH4(SO4)2, 0.5 M NACL, 0.1 M NA CITRATE, PH 6.5
分辨率 2.20 Å R-free 0.223
2VJF Crystal Structure of the MDM2-MDMX RING Domain Heterodimer 提交 2007-12-10 Assembly 1 蛋白异源复合物 异源复合物;蛋白 × 2 PDB 声明:dimeric(2) 与蛋白数一致
链 B 428–490(63 aa) 片段:RESIDUES 428-490
未记录 ZN ZINC ION × 4 X-RAY DIFFRACTION
X-ray结晶条件 pH 6.5;1.8 M NH4(SO4)2, 0.5 M NACL, 0.1 M NA CITRATE, PH 6.5
分辨率 2.30 Å R-free 0.234
2VJF Crystal Structure of the MDM2-MDMX RING Domain Heterodimer 提交 2007-12-10 Assembly 2 蛋白异源复合物 异源复合物;蛋白 × 2 PDB 声明:dimeric(2) 与蛋白数一致
链 D 428–490(63 aa) 片段:RESIDUES 428-490
未记录 ZN ZINC ION × 4 FLC CITRATE ANION × 1 X-RAY DIFFRACTION
X-ray结晶条件 pH 6.5;1.8 M NH4(SO4)2, 0.5 M NACL, 0.1 M NA CITRATE, PH 6.5
分辨率 2.30 Å R-free 0.234
2VYR Structure of human MDM4 N-terminal domain bound to a single domain antibody 提交 2008-07-28 Assembly 1 蛋白异源复合物 异源复合物;蛋白 × 12 PDB 声明:dodecameric(12) 与蛋白数一致
链 A 16–116(101 aa) 片段:RESIDUES 16-116
链 B 16–116(101 aa) 片段:RESIDUES 16-116
链 C 16–116(101 aa) 片段:RESIDUES 16-116
链 D 16–116(101 aa) 片段:RESIDUES 16-116
未记录 SO4 SULFATE ION × 4 X-RAY DIFFRACTION
X-ray结晶条件 pH 7;SE-MET: 20% PEG 3350, 0.2 M MGCL2, 1MM TRIS PH 7.0, 5MM B-ME, PROTEIN 10MG/ML. NATIVE: 1.6M AMMONIUM SULPHATE, 0.5M LITHIUM CHLORIDE, 1MM TRIS, PH 7.0, 5MM B-ME, PROTEIN 10MG/ML
分辨率 2.00 Å R-free 0.248
3DAB Structure of the human Mdmx protein bound to the p53 tumor suppressor transactivation domain 提交 2008-05-29 Assembly 1 蛋白异源复合物 异源复合物;蛋白 × 2 PDB 声明:dimeric(2) 与蛋白数一致
链 A 23–111(89 aa) 片段:UNP residues 23-111
未记录 未记录非水小分子 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, SITTING DROP;pH 6.5;300 K;25% PEG3350, 0.1M MES, pH6.5, VAPOR DIFFUSION, SITTING DROP, temperature 300K
分辨率 1.90 Å R-free 0.257
3DAB Structure of the human Mdmx protein bound to the p53 tumor suppressor transactivation domain 提交 2008-05-29 Assembly 2 蛋白异源复合物 异源复合物;蛋白 × 2 PDB 声明:dimeric(2) 与蛋白数一致
链 C 23–111(89 aa) 片段:UNP residues 23-111
未记录 未记录非水小分子 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, SITTING DROP;pH 6.5;300 K;25% PEG3350, 0.1M MES, pH6.5, VAPOR DIFFUSION, SITTING DROP, temperature 300K
分辨率 1.90 Å R-free 0.257
3DAB Structure of the human Mdmx protein bound to the p53 tumor suppressor transactivation domain 提交 2008-05-29 Assembly 3 蛋白异源复合物 异源复合物;蛋白 × 2 PDB 声明:dimeric(2) 与蛋白数一致
链 E 23–111(89 aa) 片段:UNP residues 23-111
未记录 未记录非水小分子 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, SITTING DROP;pH 6.5;300 K;25% PEG3350, 0.1M MES, pH6.5, VAPOR DIFFUSION, SITTING DROP, temperature 300K
分辨率 1.90 Å R-free 0.257
3DAB Structure of the human Mdmx protein bound to the p53 tumor suppressor transactivation domain 提交 2008-05-29 Assembly 4 蛋白异源复合物 异源复合物;蛋白 × 2 PDB 声明:dimeric(2) 与蛋白数一致
链 G 23–111(89 aa) 片段:UNP residues 23-111
未记录 未记录非水小分子 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, SITTING DROP;pH 6.5;300 K;25% PEG3350, 0.1M MES, pH6.5, VAPOR DIFFUSION, SITTING DROP, temperature 300K
分辨率 1.90 Å R-free 0.257
3EQY Crystal structure of human MDMX in complex with a 12-mer peptide inhibitor 提交 2008-10-01 Assembly 1 蛋白异源复合物 异源复合物;蛋白 × 2 PDB 声明:dimeric(2) 与蛋白数一致
链 A 24–108(85 aa) 片段:UNP residues residues 24-108
突变:Q68A, Q69A, E70A GAI GUANIDINE × 1 PO4 PHOSPHATE ION × 2 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, HANGING DROP;pH 7.5;298 K;0.1M HEPES, 0.8 M sodium phosphate, 0.8 M potassium phosphate, pH 7.5, VAPOR DIFFUSION, HANGING DROP, temperature 298K
分辨率 1.63 Å R-free 0.169
3EQY Crystal structure of human MDMX in complex with a 12-mer peptide inhibitor 提交 2008-10-01 Assembly 2 蛋白异源复合物 异源复合物;蛋白 × 2 PDB 声明:dimeric(2) 与蛋白数一致
链 B 24–108(85 aa) 片段:UNP residues residues 24-108
突变:Q68A, Q69A, E70A GAI GUANIDINE × 1 PO4 PHOSPHATE ION × 2 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, HANGING DROP;pH 7.5;298 K;0.1M HEPES, 0.8 M sodium phosphate, 0.8 M potassium phosphate, pH 7.5, VAPOR DIFFUSION, HANGING DROP, temperature 298K
分辨率 1.63 Å R-free 0.169
3FDO Structure of human MDMX in complex with high affinity peptide 提交 2008-11-26 Assembly 1 蛋白单体 单体;蛋白 × 1 PDB 声明:monomeric(1) 与蛋白数一致
链 A 23–111(89 aa) 片段:p53 binding domain, UNP residues 23-111
未记录 MG MAGNESIUM ION × 3 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, SITTING DROP;pH 7.3;290 K;4.3M NaCl, 100mM Hepes, pH7.3, VAPOR DIFFUSION, SITTING DROP, temperature 290K
分辨率 1.40 Å R-free 0.247
3FDO Structure of human MDMX in complex with high affinity peptide 提交 2008-11-26 Assembly 3 蛋白异源复合物 异源复合物;蛋白 × 4 PDB 声明:tetrameric(4) 与蛋白数一致
链 A 23–111(89 aa) 片段:p53 binding domain, UNP residues 23-111
未记录 MG MAGNESIUM ION × 10 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, SITTING DROP;pH 7.3;290 K;4.3M NaCl, 100mM Hepes, pH7.3, VAPOR DIFFUSION, SITTING DROP, temperature 290K
分辨率 1.40 Å R-free 0.247
3FDO Structure of human MDMX in complex with high affinity peptide 提交 2008-11-26 Assembly 4 蛋白异源复合物 异源复合物;蛋白 × 4 PDB 声明:tetrameric(4) 与蛋白数一致
链 A 23–111(89 aa) 片段:p53 binding domain, UNP residues 23-111
未记录 MG MAGNESIUM ION × 10 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, SITTING DROP;pH 7.3;290 K;4.3M NaCl, 100mM Hepes, pH7.3, VAPOR DIFFUSION, SITTING DROP, temperature 290K
分辨率 1.40 Å R-free 0.247
3FE7 Crystal Structure of HdmX bound to the p53-peptidomimetic Ac-Phe-Met-Aib-Pmp-Trp-Glu-Ac3c-Leu-NH2 at 1.35A 提交 2008-11-28 Assembly 1 蛋白异源复合物 异源复合物;蛋白 × 2 PDB 声明:dimeric(2) 与蛋白数一致
链 A 14–111(98 aa) 片段:N-terminal domain, UNP residues 14-111
突变:C17S 未记录非水小分子 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, HANGING DROP;pH 6;277 K;3.1M AmSo4, 1% MPD, 4% polypropyleneglycol, 0.1M MES, pH6.0, VAPOR DIFFUSION, HANGING DROP, temperature 277K
分辨率 1.35 Å R-free 0.209
3FEA Crystal Structure of HdmX bound to the p53-peptidomimetic Ac-Phe-Met-Aib-Pmp-6-Cl-Trp-Glu-Ac3c-Leu-NH2 at 1.33A 提交 2008-11-28 Assembly 1 蛋白异源复合物 异源复合物;蛋白 × 2 PDB 声明:dimeric(2) 与蛋白数一致
链 A 14–111(98 aa) 片段:N-terminal domain, UNP residues 14-111
突变:C17S MPD (4S)-2-METHYL-2,4-PENTANEDIOL × 1 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, HANGING DROP;pH 6;277 K;3.1M AmSo4, 1% MPD, 0.1M MES, pH6.0, VAPOR DIFFUSION, HANGING DROP, temperature 277K
分辨率 1.33 Å R-free 0.206
3JZO Human MDMX liganded with a 12mer peptide (pDI) 提交 2009-09-23 Assembly 1 蛋白异源复合物 异源复合物;蛋白 × 2 PDB 声明:dimeric(2) 与蛋白数一致
链 A 23–111(89 aa)
未记录 K POTASSIUM ION × 1 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, HANGING DROP;pH 8.2;292 K;1.4 M Na/K phosphate, pH 8.2, VAPOR DIFFUSION, HANGING DROP, temperature 292K
分辨率 1.80 Å R-free 0.207
3JZP Human MDMX liganded with a 12mer peptide inhibitor (pDI6W) 提交 2009-09-24 Assembly 1 蛋白异源复合物 异源复合物;蛋白 × 2 PDB 声明:dimeric(2) 与蛋白数一致
链 A 23–111(89 aa)
未记录 K POTASSIUM ION × 1 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, HANGING DROP;pH 8.2;292 K;1.4 M Na/K phosphate, pH 8.2, VAPOR DIFFUSION, HANGING DROP, temperature 292K
分辨率 1.74 Å R-free 0.217
3JZQ Human MDMX liganded with a 12mer peptide inhibitor (pDIQ) 提交 2009-09-24 Assembly 1 蛋白异源复合物 异源复合物;蛋白 × 2 PDB 声明:dimeric(2) 与蛋白数一致
链 A 23–111(89 aa)
未记录 未记录非水小分子 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, HANGING DROP;pH 7.4;292 K;2.1 M ammonium sulfate, 10 mM Tris HCl, pH 7.4, VAPOR DIFFUSION, HANGING DROP, temperature 292K
分辨率 1.80 Å R-free 0.224
3JZQ Human MDMX liganded with a 12mer peptide inhibitor (pDIQ) 提交 2009-09-24 Assembly 2 蛋白异源复合物 异源复合物;蛋白 × 2 PDB 声明:dimeric(2) 与蛋白数一致
链 B 23–111(89 aa)
未记录 SO4 SULFATE ION × 1 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, HANGING DROP;pH 7.4;292 K;2.1 M ammonium sulfate, 10 mM Tris HCl, pH 7.4, VAPOR DIFFUSION, HANGING DROP, temperature 292K
分辨率 1.80 Å R-free 0.224
3LBJ Structure of human MDMX protein in complex with a small molecule inhibitor 提交 2010-01-08 Assembly 1 蛋白单体 单体;蛋白 × 1 PDB 声明:monomeric(1) 与蛋白数一致
链 E 23–111(89 aa) 片段:p53 binding domain
未记录 WW8 N-[(3S)-1-({6-chloro-3-[1-(4-chlorobenzyl)-4-phenyl-1H-imidazol-5-yl]-1H-indol-2-yl}carbonyl)pyrrolidin-3-yl]-N,N',N'-trimethylpropane-1,3-diamine × 2 SO4 SULFATE ION × 1 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, SITTING DROP;pH 5.6;300 K;0.2M Na/K-tartrate, 0.1M Tri-sodium-citrate, 2M ammonium sulfate, pH 5.6, VAPOR DIFFUSION, SITTING DROP, temperature 300K
分辨率 1.50 Å R-free 0.206
3U15 Structure of hDMX with Dimer Inducing Indolyl Hydantoin RO-2443 提交 2011-09-29 Assembly 1 蛋白同源多聚体 同源多聚体;蛋白 × 2 PDB 声明:dimeric(2) 与蛋白数一致
链 A 14–111(98 aa) 片段:unp residues 14-111
链 B 14–111(98 aa) 片段:unp residues 14-111
突变:C17S 突变:C17S 03M (5Z)-5-[(6-chloro-7-methyl-1H-indol-3-yl)methylidene]-3-(3,4-difluorobenzyl)imidazolidine-2,4-dione × 2 SO4 SULFATE ION × 1 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, SITTING DROP;pH 7.5;277 K;1.4-2.0M ammonium sulfate 1.4-2.0M NaCl, pH 7.5, VAPOR DIFFUSION, SITTING DROP, temperature 277K
分辨率 1.80 Å R-free 0.238
3U15 Structure of hDMX with Dimer Inducing Indolyl Hydantoin RO-2443 提交 2011-09-29 Assembly 2 蛋白同源多聚体 同源多聚体;蛋白 × 2 PDB 声明:dimeric(2) 与蛋白数一致
链 C 14–111(98 aa) 片段:unp residues 14-111
链 D 14–111(98 aa) 片段:unp residues 14-111
突变:C17S 突变:C17S 03M (5Z)-5-[(6-chloro-7-methyl-1H-indol-3-yl)methylidene]-3-(3,4-difluorobenzyl)imidazolidine-2,4-dione × 2 SO4 SULFATE ION × 1 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, SITTING DROP;pH 7.5;277 K;1.4-2.0M ammonium sulfate 1.4-2.0M NaCl, pH 7.5, VAPOR DIFFUSION, SITTING DROP, temperature 277K
分辨率 1.80 Å R-free 0.238
4RXZ Crystal Structure of MDMX phosporylated Tyr99 in complex with a 12-mer peptide 提交 2014-12-12 Assembly 1 蛋白异源复合物 异源复合物;蛋白 × 2 PDB 声明:dimeric(2) 与蛋白数一致
链 A 24–108(85 aa)
非标准单体:是(mmCIF未提供具体位点) 未记录非水小分子 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, HANGING DROP;pH 6.5;298 K;12% isopropanol, 0.1M MES pH 6.5 and 10% PEG5000 MME, VAPOR DIFFUSION, HANGING DROP, temperature 298K
分辨率 1.55 Å R-free 0.220
4RXZ Crystal Structure of MDMX phosporylated Tyr99 in complex with a 12-mer peptide 提交 2014-12-12 Assembly 2 蛋白异源复合物 异源复合物;蛋白 × 2 PDB 声明:dimeric(2) 与蛋白数一致
链 B 24–108(85 aa)
非标准单体:是(mmCIF未提供具体位点) 未记录非水小分子 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, HANGING DROP;pH 6.5;298 K;12% isopropanol, 0.1M MES pH 6.5 and 10% PEG5000 MME, VAPOR DIFFUSION, HANGING DROP, temperature 298K
分辨率 1.55 Å R-free 0.220
5MNJ Structure of MDM2-MDMX-UbcH5B-ubiquitin complex 提交 2016-12-13 Assembly 1 蛋白异源复合物 异源复合物;蛋白 × 4 PDB 声明:tetrameric(4) 与蛋白数一致
链 D 427–490(64 aa)
未记录 ZN ZINC ION × 4 SO4 SULFATE ION × 1 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, HANGING DROP;292 K;0.1 M Tris-HCl, pH 8.5, 0.175 M Li2SO4 and 16-20 %(v/v) PEG 3350
分辨率 2.16 Å R-free 0.231
5MNJ Structure of MDM2-MDMX-UbcH5B-ubiquitin complex 提交 2016-12-13 Assembly 2 蛋白异源复合物 异源复合物;蛋白 × 4 PDB 声明:tetrameric(4) 与蛋白数一致
链 H 427–490(64 aa)
未记录 ZN ZINC ION × 4 SO4 SULFATE ION × 1 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, HANGING DROP;292 K;0.1 M Tris-HCl, pH 8.5, 0.175 M Li2SO4 and 16-20 %(v/v) PEG 3350
分辨率 2.16 Å R-free 0.231
5UML CRYSTAL STRUCTURE OF HUMAN MDMX IN COMPLEX WITH 12-MER PEPTIDE INHIBITOR M3 提交 2017-01-27 Assembly 1 蛋白异源复合物 异源复合物;蛋白 × 2 PDB 声明:dimeric(2) 与蛋白数一致
链 A 24–108(85 aa) 片段:residues 24-108
突变:Q68A,Q69A,E70A 未记录非水小分子 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, HANGING DROP;pH 4.6;298 K;14% (v/v) 2-Propanol ,70 mM Sodium acetate/ Hydrochloric acid pH 4.6, 140 mM Calcium chloride, 30% (v/v) Glycerol
分辨率 3.00 Å R-free 0.315
5UML CRYSTAL STRUCTURE OF HUMAN MDMX IN COMPLEX WITH 12-MER PEPTIDE INHIBITOR M3 提交 2017-01-27 Assembly 2 蛋白异源复合物 异源复合物;蛋白 × 2 PDB 声明:dimeric(2) 与蛋白数一致
链 B 24–108(85 aa) 片段:residues 24-108
突变:Q68A,Q69A,E70A 未记录非水小分子 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, HANGING DROP;pH 4.6;298 K;14% (v/v) 2-Propanol ,70 mM Sodium acetate/ Hydrochloric acid pH 4.6, 140 mM Calcium chloride, 30% (v/v) Glycerol
分辨率 3.00 Å R-free 0.315
5UML CRYSTAL STRUCTURE OF HUMAN MDMX IN COMPLEX WITH 12-MER PEPTIDE INHIBITOR M3 提交 2017-01-27 Assembly 3 蛋白异源复合物 异源复合物;蛋白 × 2 PDB 声明:dimeric(2) 与蛋白数一致
链 E 24–108(85 aa) 片段:residues 24-108
突变:Q68A,Q69A,E70A 未记录非水小分子 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, HANGING DROP;pH 4.6;298 K;14% (v/v) 2-Propanol ,70 mM Sodium acetate/ Hydrochloric acid pH 4.6, 140 mM Calcium chloride, 30% (v/v) Glycerol
分辨率 3.00 Å R-free 0.315
5UML CRYSTAL STRUCTURE OF HUMAN MDMX IN COMPLEX WITH 12-MER PEPTIDE INHIBITOR M3 提交 2017-01-27 Assembly 4 蛋白异源复合物 异源复合物;蛋白 × 2 PDB 声明:dimeric(2) 与蛋白数一致
链 G 24–108(85 aa) 片段:residues 24-108
突变:Q68A,Q69A,E70A 未记录非水小分子 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, HANGING DROP;pH 4.6;298 K;14% (v/v) 2-Propanol ,70 mM Sodium acetate/ Hydrochloric acid pH 4.6, 140 mM Calcium chloride, 30% (v/v) Glycerol
分辨率 3.00 Å R-free 0.315
5VK1 Crystal structure of human MDM4 in complex with a 12-mer lysine-cysteine side chain dithiocarbamate stapled peptide inhibitor PMI 提交 2017-04-20 Assembly 1 蛋白异源复合物 异源复合物;蛋白 × 2 PDB 声明:dimeric(2) 与蛋白数一致
链 A 24–108(85 aa) 片段:residues 24-108
突变:Q68A, Q69A, E70A 未记录非水小分子 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, HANGING DROP;pH 8.5;294 K;30% 2-propanol, 30% PEG 3350, and 100 mM Tris-HCl pH 8.5
分辨率 2.69 Å R-free 0.335
5VK1 Crystal structure of human MDM4 in complex with a 12-mer lysine-cysteine side chain dithiocarbamate stapled peptide inhibitor PMI 提交 2017-04-20 Assembly 2 蛋白异源复合物 异源复合物;蛋白 × 2 PDB 声明:dimeric(2) 与蛋白数一致
链 C 24–108(85 aa) 片段:residues 24-108
突变:Q68A, Q69A, E70A 未记录非水小分子 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, HANGING DROP;pH 8.5;294 K;30% 2-propanol, 30% PEG 3350, and 100 mM Tris-HCl pH 8.5
分辨率 2.69 Å R-free 0.335
5VK1 Crystal structure of human MDM4 in complex with a 12-mer lysine-cysteine side chain dithiocarbamate stapled peptide inhibitor PMI 提交 2017-04-20 Assembly 3 蛋白异源复合物 异源复合物;蛋白 × 2 PDB 声明:dimeric(2) 与蛋白数一致
链 E 24–108(85 aa) 片段:residues 24-108
突变:Q68A, Q69A, E70A 未记录非水小分子 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, HANGING DROP;pH 8.5;294 K;30% 2-propanol, 30% PEG 3350, and 100 mM Tris-HCl pH 8.5
分辨率 2.69 Å R-free 0.335
5VK1 Crystal structure of human MDM4 in complex with a 12-mer lysine-cysteine side chain dithiocarbamate stapled peptide inhibitor PMI 提交 2017-04-20 Assembly 4 蛋白异源复合物 异源复合物;蛋白 × 2 PDB 声明:dimeric(2) 与蛋白数一致
链 G 24–108(85 aa) 片段:residues 24-108
突变:Q68A, Q69A, E70A 未记录非水小分子 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, HANGING DROP;pH 8.5;294 K;30% 2-propanol, 30% PEG 3350, and 100 mM Tris-HCl pH 8.5
分辨率 2.69 Å R-free 0.335
5VK1 Crystal structure of human MDM4 in complex with a 12-mer lysine-cysteine side chain dithiocarbamate stapled peptide inhibitor PMI 提交 2017-04-20 Assembly 5 蛋白异源复合物 异源复合物;蛋白 × 2 PDB 声明:dimeric(2) 与蛋白数一致
链 I 24–108(85 aa) 片段:residues 24-108
突变:Q68A, Q69A, E70A 未记录非水小分子 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, HANGING DROP;pH 8.5;294 K;30% 2-propanol, 30% PEG 3350, and 100 mM Tris-HCl pH 8.5
分辨率 2.69 Å R-free 0.335
5VK1 Crystal structure of human MDM4 in complex with a 12-mer lysine-cysteine side chain dithiocarbamate stapled peptide inhibitor PMI 提交 2017-04-20 Assembly 6 蛋白异源复合物 异源复合物;蛋白 × 2 PDB 声明:dimeric(2) 与蛋白数一致
链 K 24–108(85 aa) 片段:residues 24-108
突变:Q68A, Q69A, E70A 未记录非水小分子 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, HANGING DROP;pH 8.5;294 K;30% 2-propanol, 30% PEG 3350, and 100 mM Tris-HCl pH 8.5
分辨率 2.69 Å R-free 0.335
5VK1 Crystal structure of human MDM4 in complex with a 12-mer lysine-cysteine side chain dithiocarbamate stapled peptide inhibitor PMI 提交 2017-04-20 Assembly 7 蛋白异源复合物 异源复合物;蛋白 × 2 PDB 声明:dimeric(2) 与蛋白数一致
链 M 24–108(85 aa) 片段:residues 24-108
突变:Q68A, Q69A, E70A 未记录非水小分子 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, HANGING DROP;pH 8.5;294 K;30% 2-propanol, 30% PEG 3350, and 100 mM Tris-HCl pH 8.5
分辨率 2.69 Å R-free 0.335
5VK1 Crystal structure of human MDM4 in complex with a 12-mer lysine-cysteine side chain dithiocarbamate stapled peptide inhibitor PMI 提交 2017-04-20 Assembly 8 蛋白异源复合物 异源复合物;蛋白 × 2 PDB 声明:dimeric(2) 与蛋白数一致
链 O 24–108(85 aa) 片段:residues 24-108
突变:Q68A, Q69A, E70A 未记录非水小分子 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, HANGING DROP;pH 8.5;294 K;30% 2-propanol, 30% PEG 3350, and 100 mM Tris-HCl pH 8.5
分辨率 2.69 Å R-free 0.335
6Q9Q HDMX (14-111; C17S) COMPLEXED WITH COMPOUND 13 AT 2.1A; Structural states of Hdm2 and HdmX: X-ray elucidation of adaptations and binding interactions for different chemical compound classes 提交 2018-12-18 Assembly 1 蛋白单体 单体;蛋白 × 1 PDB 声明:monomeric(1) 与蛋白数一致
链 A 14–111(98 aa) 片段:N-terminal domain, p53 binding domain
突变:C17S HUE 6-chloranyl-3-[3-[(1~{S})-1-(4-chlorophenyl)ethyl]-5-phenyl-imidazol-4-yl]-~{N}-[2-(4-cyclohexylpiperazin-1-yl)ethyl]-1~{H}-indole-2-carboxamide × 1 O4B 1,4,7,10,13,16-HEXAOXACYCLOOCTADECANE × 1 SO4 SULFATE ION × 1 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, HANGING DROP;pH 7.5;298 K;2.6M AmSO4, 4% w/v 18-crown-ether, 0.1M HEPES
分辨率 2.10 Å R-free 0.252
6Q9Q HDMX (14-111; C17S) COMPLEXED WITH COMPOUND 13 AT 2.1A; Structural states of Hdm2 and HdmX: X-ray elucidation of adaptations and binding interactions for different chemical compound classes 提交 2018-12-18 Assembly 2 蛋白单体 单体;蛋白 × 1 PDB 声明:monomeric(1) 与蛋白数一致
链 B 14–111(98 aa) 片段:N-terminal domain, p53 binding domain
突变:C17S HUE 6-chloranyl-3-[3-[(1~{S})-1-(4-chlorophenyl)ethyl]-5-phenyl-imidazol-4-yl]-~{N}-[2-(4-cyclohexylpiperazin-1-yl)ethyl]-1~{H}-indole-2-carboxamide × 1 O4B 1,4,7,10,13,16-HEXAOXACYCLOOCTADECANE × 2 SO4 SULFATE ION × 1 GOL GLYCEROL × 1 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, HANGING DROP;pH 7.5;298 K;2.6M AmSO4, 4% w/v 18-crown-ether, 0.1M HEPES
分辨率 2.10 Å R-free 0.252
6Q9Q HDMX (14-111; C17S) COMPLEXED WITH COMPOUND 13 AT 2.1A; Structural states of Hdm2 and HdmX: X-ray elucidation of adaptations and binding interactions for different chemical compound classes 提交 2018-12-18 Assembly 3 蛋白单体 单体;蛋白 × 1 PDB 声明:monomeric(1) 与蛋白数一致
链 C 14–111(98 aa) 片段:N-terminal domain, p53 binding domain
突变:C17S HUE 6-chloranyl-3-[3-[(1~{S})-1-(4-chlorophenyl)ethyl]-5-phenyl-imidazol-4-yl]-~{N}-[2-(4-cyclohexylpiperazin-1-yl)ethyl]-1~{H}-indole-2-carboxamide × 1 O4B 1,4,7,10,13,16-HEXAOXACYCLOOCTADECANE × 1 SO4 SULFATE ION × 1 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, HANGING DROP;pH 7.5;298 K;2.6M AmSO4, 4% w/v 18-crown-ether, 0.1M HEPES
分辨率 2.10 Å R-free 0.252
6Q9Q HDMX (14-111; C17S) COMPLEXED WITH COMPOUND 13 AT 2.1A; Structural states of Hdm2 and HdmX: X-ray elucidation of adaptations and binding interactions for different chemical compound classes 提交 2018-12-18 Assembly 4 蛋白单体 单体;蛋白 × 1 PDB 声明:monomeric(1) 与蛋白数一致
链 D 14–111(98 aa) 片段:N-terminal domain, p53 binding domain
突变:C17S HUE 6-chloranyl-3-[3-[(1~{S})-1-(4-chlorophenyl)ethyl]-5-phenyl-imidazol-4-yl]-~{N}-[2-(4-cyclohexylpiperazin-1-yl)ethyl]-1~{H}-indole-2-carboxamide × 1 O4B 1,4,7,10,13,16-HEXAOXACYCLOOCTADECANE × 1 SO4 SULFATE ION × 3 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, HANGING DROP;pH 7.5;298 K;2.6M AmSO4, 4% w/v 18-crown-ether, 0.1M HEPES
分辨率 2.10 Å R-free 0.252
6Q9S HDMX (14-111; C17S) COMPLEXED WITH COMPOUND 14 AT 2.4A: Structural states of Hdm2 and HdmX: X-ray elucidation of adaptations and binding interactions for different chemical compound classes 提交 2018-12-18 Assembly 1 蛋白单体 单体;蛋白 × 1 PDB 声明:monomeric(1) 与蛋白数一致
链 A 14–111(98 aa) 片段:N-terminal domain, p53 binding domain
突变:C17S HRN 3-[[6-chloranyl-3-[3-[(1~{S})-1-(2,4-dichlorophenyl)ethyl]-5-phenyl-imidazol-4-yl]-1~{H}-indol-2-yl]carbonylamino]-4-[4-(2-oxidanylidene-1,3-oxazinan-3-yl)piperidin-1-yl]benzoic acid × 1 O4B 1,4,7,10,13,16-HEXAOXACYCLOOCTADECANE × 4 SO4 SULFATE ION × 1 NA SODIUM ION × 2 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, HANGING DROP;pH 7.5;298 K;2.25M AmSO4, 6% w/v 18-crown-ether, 0.1M HEPES
分辨率 2.40 Å R-free 0.268
6Q9S HDMX (14-111; C17S) COMPLEXED WITH COMPOUND 14 AT 2.4A: Structural states of Hdm2 and HdmX: X-ray elucidation of adaptations and binding interactions for different chemical compound classes 提交 2018-12-18 Assembly 2 蛋白单体 单体;蛋白 × 1 PDB 声明:monomeric(1) 与蛋白数一致
链 C 14–111(98 aa) 片段:N-terminal domain, p53 binding domain
突变:C17S HRN 3-[[6-chloranyl-3-[3-[(1~{S})-1-(2,4-dichlorophenyl)ethyl]-5-phenyl-imidazol-4-yl]-1~{H}-indol-2-yl]carbonylamino]-4-[4-(2-oxidanylidene-1,3-oxazinan-3-yl)piperidin-1-yl]benzoic acid × 1 O4B 1,4,7,10,13,16-HEXAOXACYCLOOCTADECANE × 7 SO4 SULFATE ION × 2 NA SODIUM ION × 1 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, HANGING DROP;pH 7.5;298 K;2.25M AmSO4, 6% w/v 18-crown-ether, 0.1M HEPES
分辨率 2.40 Å R-free 0.268
6Q9S HDMX (14-111; C17S) COMPLEXED WITH COMPOUND 14 AT 2.4A: Structural states of Hdm2 and HdmX: X-ray elucidation of adaptations and binding interactions for different chemical compound classes 提交 2018-12-18 Assembly 3 蛋白单体 单体;蛋白 × 1 PDB 声明:monomeric(1) 与蛋白数一致
链 B 14–111(98 aa) 片段:N-terminal domain, p53 binding domain
突变:C17S HRN 3-[[6-chloranyl-3-[3-[(1~{S})-1-(2,4-dichlorophenyl)ethyl]-5-phenyl-imidazol-4-yl]-1~{H}-indol-2-yl]carbonylamino]-4-[4-(2-oxidanylidene-1,3-oxazinan-3-yl)piperidin-1-yl]benzoic acid × 1 O4B 1,4,7,10,13,16-HEXAOXACYCLOOCTADECANE × 2 SO4 SULFATE ION × 2 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, HANGING DROP;pH 7.5;298 K;2.25M AmSO4, 6% w/v 18-crown-ether, 0.1M HEPES
分辨率 2.40 Å R-free 0.268
6Q9U HDMX (14-111; C17S) COMPLEXED WITH COMPOUND 12 AT 2.4A; Structural states of Hdm2 and HdmX: X-ray elucidation of adaptations and binding interactions for different chemical compound classes 提交 2018-12-18 Assembly 1 蛋白单体 单体;蛋白 × 1 PDB 声明:monomeric(1) 与蛋白数一致
链 A 14–111(98 aa) 片段:N-terminal domain, p53 binding domain
突变:C17S HRE 4-[(4~{S})-5-(5-chloranyl-2-oxidanylidene-1~{H}-pyridin-3-yl)-2-[2-(dimethylamino)-4-methoxy-pyrimidin-5-yl]-6-oxidanylidene-3-propan-2-yl-4~{H}-pyrrolo[3,4-c]pyrazol-4-yl]benzenecarbonitrile × 1 O4B 1,4,7,10,13,16-HEXAOXACYCLOOCTADECANE × 1 CL CHLORIDE ION × 1 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, HANGING DROP;pH 7.5;298 K;2.3M AmSO4, 2% w/v 18-crown-ether, 0.1M HEPES
分辨率 2.40 Å R-free 0.265
6Q9W X-ray structure of compound 15 bound to HdmX: Structural states of Hdm2 and HdmX: X-ray elucidation of adaptations and binding interactions for different chemical compound classes 提交 2018-12-18 Assembly 1 蛋白单体 单体;蛋白 × 1 PDB 声明:monomeric(1) 与蛋白数一致
链 A 14–111(98 aa) 片段:N-terminal domain, p53 binding domain
突变:C17S HRT (4~{S})-4-(4-chlorophenyl)-5-[(1~{S})-1-(3-chlorophenyl)ethyl]-2-(2,4-dimethoxypyrimidin-5-yl)-3-propan-2-yl-4~{H}-pyrrolo[3,4-d]imidazol-6-one × 1 SO4 SULFATE ION × 1 O4B 1,4,7,10,13,16-HEXAOXACYCLOOCTADECANE × 2 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, HANGING DROP;pH 7.5;298 K;2.25M AmSO4, 4% w/v 18-crown-ether, 0.1M HEPES
分辨率 1.55 Å R-free 0.240
6Q9W X-ray structure of compound 15 bound to HdmX: Structural states of Hdm2 and HdmX: X-ray elucidation of adaptations and binding interactions for different chemical compound classes 提交 2018-12-18 Assembly 2 蛋白单体 单体;蛋白 × 1 PDB 声明:monomeric(1) 与蛋白数一致
链 B 14–111(98 aa) 片段:N-terminal domain, p53 binding domain
突变:C17S HRT (4~{S})-4-(4-chlorophenyl)-5-[(1~{S})-1-(3-chlorophenyl)ethyl]-2-(2,4-dimethoxypyrimidin-5-yl)-3-propan-2-yl-4~{H}-pyrrolo[3,4-d]imidazol-6-one × 1 SO4 SULFATE ION × 1 O4B 1,4,7,10,13,16-HEXAOXACYCLOOCTADECANE × 2 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, HANGING DROP;pH 7.5;298 K;2.25M AmSO4, 4% w/v 18-crown-ether, 0.1M HEPES
分辨率 1.55 Å R-free 0.240
6Q9Y HDMX (14-111; C17S) COMPLEXED WITH COMPOUND 16 AT 1.20A; Structural states of Hdm2 and HdmX: X-ray elucidation of adaptations and binding interactions for different chemical compound classes 提交 2018-12-18 Assembly 1 蛋白单体 单体;蛋白 × 1 PDB 声明:monomeric(1) 与蛋白数一致
链 A 14–111(98 aa) 片段:N-terminal domain, p53 binding domain
突变:C17S HRQ 7-methoxy-~{N}-[(3~{S})-1-(4-methylphenyl)pyrrolidin-3-yl]-1~{H}-indole-3-carboxamide × 1 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, HANGING DROP;pH 6;298 K;2.5M AmSO4, 0.1M KSCN, 1% v/v MPD, 0.1M MES
分辨率 1.20 Å R-free 0.184
6Q9Y HDMX (14-111; C17S) COMPLEXED WITH COMPOUND 16 AT 1.20A; Structural states of Hdm2 and HdmX: X-ray elucidation of adaptations and binding interactions for different chemical compound classes 提交 2018-12-18 Assembly 2 蛋白单体 单体;蛋白 × 1 PDB 声明:monomeric(1) 与蛋白数一致
链 B 14–111(98 aa) 片段:N-terminal domain, p53 binding domain
突变:C17S HRQ 7-methoxy-~{N}-[(3~{S})-1-(4-methylphenyl)pyrrolidin-3-yl]-1~{H}-indole-3-carboxamide × 1 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, HANGING DROP;pH 6;298 K;2.5M AmSO4, 0.1M KSCN, 1% v/v MPD, 0.1M MES
分辨率 1.20 Å R-free 0.184
6YR5 14-3-3 sigma in complex with hDMX-367 peptide 提交 2020-04-19 Assembly 1 蛋白异源复合物 异源复合物;蛋白 × 4 PDB 声明:tetrameric(4) 与蛋白数一致
链 O 361–374(14 aa)
链 P 361–374(14 aa)
非标准单体:是(mmCIF未提供具体位点) 非标准单体:是(mmCIF未提供具体位点) SO4 SULFATE ION × 1 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, HANGING DROP;pH 7;277 K;0.1M Bis-Tris propane pH 7, 0.2 M Sodium citrate, 20% PEG3350
分辨率 2.25 Å R-free 0.222
6YR5 14-3-3 sigma in complex with hDMX-367 peptide 提交 2020-04-19 Assembly 2 蛋白异源复合物 异源复合物;蛋白 × 4 PDB 声明:tetrameric(4) 与蛋白数一致
链 Q 361–374(14 aa)
链 R 361–374(14 aa)
非标准单体:是(mmCIF未提供具体位点) 非标准单体:是(mmCIF未提供具体位点) 未记录非水小分子 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, HANGING DROP;pH 7;277 K;0.1M Bis-Tris propane pH 7, 0.2 M Sodium citrate, 20% PEG3350
分辨率 2.25 Å R-free 0.222
6YR7 14-3-3 sigma in complex with hDMX-342+367 peptide 提交 2020-04-19 Assembly 1 蛋白异源复合物 异源复合物;蛋白 × 4 PDB 声明:tetrameric(4) 与蛋白数一致
链 C 335–374(40 aa)
链 Q 335–374(40 aa)
非标准单体:是(mmCIF未提供具体位点) 非标准单体:是(mmCIF未提供具体位点) B3P 2-[3-(2-HYDROXY-1,1-DIHYDROXYMETHYL-ETHYLAMINO)-PROPYLAMINO]-2-HYDROXYMETHYL-PROPANE-1,3-DIOL × 1 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, SITTING DROP;pH 8;277 K;Sodium citrate tribasic dihydrate, PEG3350, Bis-Tris propane pH8
分辨率 2.10 Å R-free 0.246
7C3Q Human MdmX protein in complex with Nutlin3a 提交 2020-05-13 Assembly 1 蛋白单体 单体;蛋白 × 1 PDB 声明:monomeric(1) 与蛋白数一致
链 A 23–108(86 aa)
未记录 O4B 1,4,7,10,13,16-HEXAOXACYCLOOCTADECANE × 1 NUT 4-({(4S,5R)-4,5-bis(4-chlorophenyl)-2-[4-methoxy-2-(propan-2-yloxy)phenyl]-4,5-dihydro-1H-imidazol-1-yl}carbonyl)piperazin-2-one × 1 PEG DI(HYDROXYETHYL)ETHER × 1 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, SITTING DROP;pH 6.5;291 K;0.1 M HEPES sodium salt pH 7.5, 1.6 M Ammonium sulfate, 2%(w/v) PEG 1000
分辨率 1.80 Å R-free 0.241
7C3Y Crystal structure of the N-terminal domain of human MdmX protein in complex with Nutlin3a 提交 2020-05-14 Assembly 1 蛋白单体 单体;蛋白 × 1 PDB 声明:monomeric(1) 与蛋白数一致
链 A 23–108(86 aa)
未记录 O4B 1,4,7,10,13,16-HEXAOXACYCLOOCTADECANE × 1 NUT 4-({(4S,5R)-4,5-bis(4-chlorophenyl)-2-[4-methoxy-2-(propan-2-yloxy)phenyl]-4,5-dihydro-1H-imidazol-1-yl}carbonyl)piperazin-2-one × 1 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, SITTING DROP;pH 7.5;291 K;20% v/v Tacsimate pH 7.0, 0.1 M HEPES sodium salt pH 7.5, 2% (w/v) PEG 200
分辨率 1.63 Å R-free 0.227
7C44 Crystal structure of the p53-binding domain of human MdmX protein in complex with Nutlin3a 提交 2020-05-15 Assembly 1 蛋白单体 单体;蛋白 × 1 PDB 声明:monomeric(1) 与蛋白数一致
链 A 23–108(86 aa)
未记录 NUT 4-({(4S,5R)-4,5-bis(4-chlorophenyl)-2-[4-methoxy-2-(propan-2-yloxy)phenyl]-4,5-dihydro-1H-imidazol-1-yl}carbonyl)piperazin-2-one × 1 O4B 1,4,7,10,13,16-HEXAOXACYCLOOCTADECANE × 1 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, SITTING DROP;pH 7.5;291 K;20% v/v Tacsimate pH 7.0, 0.1 M HEPES sodium salt pH 7.5, 2% (w/v) PEG 200
分辨率 1.65 Å R-free 0.265
7EL4 The crystal structure of p53p peptide fragment in complex with the N-terminal domain of MdmX 提交 2021-04-08 Assembly 1 信息不足 单体;蛋白 × 1 PDB 声明:monomeric(1) 与蛋白数一致
链 A 23–111(89 aa)
未记录 O4B 1,4,7,10,13,16-HEXAOXACYCLOOCTADECANE × 2 MG MAGNESIUM ION × 2 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, SITTING DROP;pH 7.16;291 K;0.1 M MES pH 6.5, 2 M MgSO4
分辨率 2.11 Å R-free 0.225
7KJN CRYSTAL STRUCTURE OF HUMAN MDMX IN COMPLEX WITH D-PEPTIDE INHIBITOR (DPMI-OMEGA) 提交 2020-10-26 Assembly 1 蛋白异源复合物 异源复合物;蛋白 × 3 PDB 声明:trimeric(3) 与蛋白数一致
链 A 24–108(85 aa)
突变:Q68A, Q69A, E70A 未记录非水小分子 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, SITTING DROP;pH 7.5;294 K;4M sodium chloride, 5% isopropanol, 0.1M HEPES pH 7.5
分辨率 2.80 Å R-free 0.244
7MLA Solution NMR structure of HDMX in complex with Zn and MCo-52-2 提交 2021-04-28 Assembly 1 蛋白异源复合物 异源复合物;蛋白 × 2 PDB 声明:dimeric(2) 与蛋白数一致
链 A 428–490(63 aa)
未记录 ZN ZINC ION × 2 SOLUTION NMR
NMR测量条件 pH 7;298 K;离子强度(mmCIF原始值)0.15;压力 1
NMR样品组成 0.100 mM [U-100% 13C; U-100% 15N] Hdmx, 0.100 mM MCo-52-2, 90% H2O/10% D2O | 90% H2O/10% D2O
NMR样品组成 0.100 mM Hdmx, 0.100 mM [U-100% 13C; U-100% 15N] MCo-52-2, 90% H2O/10% D2O | 90% H2O/10% D2O
分辨率未提供
8IA5 Small peptide enhances the binding of nutline-3a to N-terminal domain of MdmX 提交 2023-02-07 Assembly 1 蛋白异源复合物 异源复合物;蛋白 × 2 PDB 声明:dimeric(2) 与蛋白数一致
链 A 23–111(89 aa)
未记录 NUT 4-({(4S,5R)-4,5-bis(4-chlorophenyl)-2-[4-methoxy-2-(propan-2-yloxy)phenyl]-4,5-dihydro-1H-imidazol-1-yl}carbonyl)piperazin-2-one × 1 O4B 1,4,7,10,13,16-HEXAOXACYCLOOCTADECANE × 1 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, SITTING DROP;pH 6.5;291 K;0.1M HEPES pH6.0, 1.6M Ammonium sulfate
分辨率 1.93 Å R-free 0.284